Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Scherlinger Marc; Langlois Emmanuel; Germain Vincent; Schaeverbeke Thierry

首页> 外文期刊>Seminars in Arthritis and Rheumatism >Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

【24h】

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

机译：从发起者到BioSimilar entanErcept的接受率和社会学因素（SB4）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel (c)) to biosimilar etanercept (SB4, Benepali (c)) in patients with rheumatic disease.

机译：目的：研究影响从发起者entanercept（Enbrel（C））接受接受的接受率和因素到生物蛋白质肠杆菌（SB4，Benepali（C））中有风湿病疾病。

著录项

来源
《Seminars in Arthritis and Rheumatism》 |2019年第5期|共6页
作者
Scherlinger Marc; Langlois Emmanuel; Germain Vincent; Schaeverbeke Thierry;
展开▼
作者单位

CHU Bordeaux Serv Rhumatol Pl Amelie Raba Leon F-33076 Bordeaux France;

Univ Bordeaux 146 Rue Leo Saignat F-33076 Bordeaux France;

CHU Bordeaux Serv Rhumatol Pl Amelie Raba Leon F-33076 Bordeaux France;

CHU Bordeaux Serv Rhumatol Pl Amelie Raba Leon F-33076 Bordeaux France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
DMARDs (biologic); Patient perspective; Rheumatoid arthritis; Spondyloarthritis; Anti-TNF;

机译：DMARDS（生物学）;患者的观点;类风湿性关节炎;脊椎炎;反TNF;

相似文献

外文文献
中文文献
专利

1. Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar)to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma [J] . Yuankai Shi, Jifeng Feng, Xiaonan Hong, 中国癌症研究（英文版） . 2021,第003期
2. Biosimilars: A novel perspective in diabetes therapy [J] . Muthu Thiruvengadam, Baskar Venkidasamy, Ill-Min Chung, 亚太热带医药杂志（英文版） . 2020,第007期
3. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4) [J] . Scherlinger Marc, Langlois Emmanuel, Germain Vincent, Seminars in Arthritis and Rheumatism . 2019,第5期

机译：从发起者到BioSimilar entanErcept的接受率和社会学因素（SB4）
4. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching [J] . Cantini Fabrizio, Benucci Maurizio Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第2期

机译：强制性的，从发起者Etanercept到其生物拖尾SB4的强制性转换：在非医疗开关上可能的辐射
5. Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci [J] . Glintborg Bente, Loft Anne Gitte, Omerovic Emina, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第2期

机译：响应：“从发起人entanercept到其生物仿制物的强制性，成本驱动的切换到其生物拖尾的SB4：由Cantini和Benucci对非医用切换的可能性出现
6. Improved reagents and software for comparing biosimilar and originator therapeutic proteins: Accurate analysis of deamidationand disulfide bond scrambling [C] . Wilfred H. Tang, Marshall Bern, St John Skilton, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：改进的试剂和软件，用于比较生物仿制剂和发起者治疗蛋白质：准确分析脱胺和二硫键加扰
7. Analytical Comparability Strategies for Originators and Biosimilars [D] . Kang, Jukyung. 2019

机译：发发人和生物仿制性的分析可比性策略
8. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review [O] . Hans C. Ebbers, Burkhard Pieper, Amine Issa, 2019

机译：Etanercept初次接受治疗或转换患者的Etanercept生物仿制药SB4的真实证据：系统评价
9. SAT0134 COMPARING REAL-WORLD RETENTION RATES IN A MATCHED COHORT OF RHEUMATOID ARTHRITIS PATIENTS WHO EITHER REMAINED ON THE ETANERCEPT ORIGINATOR OR SWITCHED TO A BIOSIMILAR [O] . Lisa Baganz, Anja Strangfeld, Peter Herzer, 2019

机译：SAT0134比较现实世界的保留率在依赖于entanercept发起者或切换到生物仿制物上的类风湿性关节炎患者中的匹配队列

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

摘要

著录项

相似文献

相关主题

期刊订阅